title: The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.
abstract: BACKGROUND
  Respiratory infections are associated with clinically significant illness in patients with sickle cell disease (SCD). The 2009 H1N1 pandemic was perceived as a significant threat to this population.
  
  
  METHODS
  We undertook a chart review of all patients with SCD followed at our institution to identify those with confirmed H1N1 infection. Further chart and laboratory data was collected on affected patients to analyze clinical courses and the factors that correlated with disease severity.
  
  
  RESULTS
  Approximately half of the patients with confirmed H1N1 infection were managed successfully on an outpatient basis with oseltamivir therapy. Among the patients admitted, the most common diagnosis was acute chest syndrome (ACS). Most admitted patients had uncomplicated clinical courses, with a median length of admission of 3 days and no mortality or requirement for mechanical ventilation. A past history of ACS or reactive airway disease correlated with a higher rate of admission and of ACS incidence during the acute illness. Chronic transfusion therapy or hydroxyurea therapy with high hemoglobin F levels had a strong inverse correlation with incidence of ACS.
  
  
  CONCLUSIONS
  Our results indicate that that in general the impact of the H1N1 influenza pandemic on patients with SCD was mild but that past clinical history correlated with the severity of illness. Additionally, effective hydroxyurea therapy and chronic transfusion therapy appeared to be protective against the incidence of ACS. Our results suggest guidelines for the management of patients with SCD during future influenza pandemics as well as during seasonal influenza epidemics.
authors.affiliation: Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. alex.george@cchmc.org
authors.forename: Alex
authors.initials: A
authors.lastname: George
authors.forename: Jennifer
authors.initials: J
authors.lastname: Benton
authors.forename: Jesse
authors.initials: J
authors.lastname: Pratt
authors.forename: Mi-Ok
authors.initials: MO
authors.lastname: Kim
authors.forename: Karen A
authors.initials: KA
authors.lastname: Kalinyak
authors.forename: Theodosia A
authors.initials: TA
authors.lastname: Kalfa
authors.forename: Clinton H
authors.initials: CH
authors.lastname: Joiner
mesh_terms: D056586:Acute Chest Syndrome / Q000453:epidemiology / Q000628:therapy / Q000821:virology; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000628:therapy; D000986:Antisickling Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D002648:Child; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015994:Incidence; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D053139:Oseltamivir / Q000627:therapeutic use; D058873:Pandemics; D012189:Retrospective Studies
chemical_list: D000986:Antisickling Agents; D000998:Antiviral Agents; D053139:Oseltamivir; D006918:Hydroxyurea